12 results about "Precancerous condition" patented technology

This invention discloses a wired dual-modal imaging capsule endoscopy system, belonging to the field of medical device technology. The system includes a capsule module, a transmission and control module, a dual-modal imaging module, and a signal analysis module. The capsule module is used to achieve 360° circumferential scanning imaging of the esophageal mucosa. The transmission and control module ensures stable transmission of optical and electrical signals and precise control of capsule movement. The dual-modal imaging module integrates an optical coherence tomography submodule and a photoacoustic imaging submodule to acquire tissue morphology information and microvascular distribution information, respectively. The signal analysis module processes the dual-modal signals. This invention achieves three-dimensional high-resolution integrated imaging of the esophageal mucosa without the need for exogenous labeling agents, significantly improving the detection accuracy of early esophageal cancer and precancerous lesions.

The present invention provides a computer implemented method for the prediction of clinical outcomes in patients with cancer or pre-neoplastic conditions through the integration of genomic evolutionary, genomic and clinical. More specifically, the invention provides systems and algorithms that generate prognostic and predictive models based on the combined analysis of molecular features, inferred evolutionary routes, and clinical parameters, enabling patient risk stratification and individualized outcome estimation.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The present application provides the application of Rabdosia serra extract in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the Rabdosia serra extract includes Rabdosia serra aerial part extract, Rabdosia serra underground part extract, Rabdosia serra total part extract and eluate thereof, etc. The present application also provides the application of compounds in Rabdosia serra in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the compounds in Rabdosia serra are selected from oridonin, rabdosin C, norcantharidin, raxofelone and rabdosiin A. The present application proves that Rabdosia serra extract and the compounds in Rabdosia serra have good activity of reversing precancerous lesions of gastric cancer by constructing a cell model (MC cell model) of atrophic gastritis and precancerous lesions of gastric cancer by stimulating GES-1 cells with MNNG.

The present application relates to the field of traditional Chinese medicine, and particularly to a composition for treating chronic gastritis and application thereof, the composition is prepared from the following raw materials according to weight fraction: 8-12 parts of Fashanxia, 8-12 parts of Huangqin, 3-7 parts of Huanglian, 4-8 parts of Ganjiang, 12-18 parts of Taizishen, 12-18 parts of Baihuasheshecao, 12-16 parts of Banzhilian, 8-12 parts of E'zhu, 12-20 parts of Chaozhigu, 18-22 parts of Chaoquya, 18-22 parts of Chaomaiya, 8-12 parts of Yujin, 1-5 parts of Sanqi, 8-12 parts of Dazao and 3-8 parts of Zhigancao. The present application effectively solves the problems of lack of specific therapy and specific intervention target for reversing mucosal atrophy, intestinal metaplasia and other precancerous lesions in the prior art, provides a new idea for the mechanism research of CAG treatment by traditional Chinese medicine, and has important theoretical value and clinical conversion prospect for promoting the modernization of traditional Chinese medicine.

Non-invasive method for the diagnosis or screening of colorectal cancer and / or pre-cancerous stage thereof. The present invention refers to an in vitro method for the diagnosis of colorectal cancer and / or pre-cancerous stage thereof.

The present invention relates to methods of predicting whether a subject having a cancer or a pre-cancer would benefit from treatment with an immune checkpoint inhibitor, as well as methods for treating subjects determined to be likely to benefit from such treatment.

This invention discloses a novel application of undecanoic acid in inducing ferroptosis in laryngeal cancer cells and in the preparation of anti-laryngeal cancer drugs. For the first time, it was discovered that the known compound undecanoic acid can specifically target the mitochondria of laryngeal cancer cells, inducing mitochondrial structural damage and dysfunction. This, in turn, activates the ferroptosis pathway through multiple mechanisms, including increasing intracellular ferrous ion accumulation, increasing lipid peroxide levels, downregulating GPX4 / SLC7A11 expression, and upregulating ACSL4 expression, thereby effectively inhibiting the proliferation of laryngeal cancer cells. Based on this mechanism, this invention provides a pharmaceutical composition with undecanoic acid as the active ingredient, and its combined application with platinum-based drugs (such as cisplatin). This combined treatment exhibits a significant synergistic effect, particularly overcoming the platinum resistance of laryngeal cancer cells. This invention provides a novel drug selection and combination therapy strategy for the treatment and prevention of laryngeal cancer and precancerous lesions.

The present application relates to the technical field of biological detection, and discloses a reagent composition, a kit and application for detecting cervical cancer and precancerous lesions. MDGA2 gene, ZNF773 gene, CSDAP1 gene and CLEC14A gene. The reagent composition of the present application can realize efficient non-invasive screening of high-grade cervical lesions and cervical cancer by detecting the methylation level of a specific combination of marker genes, and has high detection specificity and sensitivity.

The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.

This invention provides the use of a reagent for detecting RNF111 S255 phosphorylation in the preparation of products for diagnosing colorectal cancer. It also provides the use of the reagent for detecting RNF111 S255 phosphorylation in the preparation of products for assessing the prognosis of colorectal cancer patients and for predicting precancerous lesions of colorectal cancer. The uses of this invention provide groundbreaking scientific evidence for the early diagnosis and prognostic stratification of colorectal cancer.